ANTIBODY-DRUG CONJUGATES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-173748 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Antibody-drug Conjugates Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANTIBODY-DRUG CONJUGATES MARKET
7.1 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 F. Hoffmann-La Roche Ltd
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Seattle Genetics, Inc.
16.3 Pfizer Inc.
16.4 Takeda Pharmaceutical Company Limited
16.5 AbbVie Inc
16.6 Immunomedics
16.7 Novartis AG
16.8 Genentech Inc.
16.9 Immunogen Inc.
16.10 Progenics Pharmaceuticals
16.11 Bayer Healthcare Pharmaceuticals
16.12 Agensys Inc.
16.13 Concortis Biotherpautics
16.14 Sanofi S.A.
16.15 Celldex Therapeutics Inc.
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TechnologyCleavable Linker
Non-cleavable Linker
By Application
Blood Cancer
 o Leukemia
 o Lymphoma
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumour
Companies
F. Hoffmann-La Roche Ltd
Seattle Genetics, Inc.
Pfizer Inc.
Takeda Pharmaceutical Company Limited
AbbVie Inc
Immunomedics
Novartis AG
Genentech Inc.
Immunogen Inc.
Progenics Pharmaceuticals
Bayer Healthcare Pharmaceuticals
Agensys Inc.
Concortis Biotherpautics
Sanofi S.A.
Celldex Therapeutics Inc.
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.